ÖAÖzlem Alhan

Özlem Alhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Özlem Alhan has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Asu Fergun Yilmaz

    Department of Hematology, Marmara University Faculty of Medicine, Istanbul, Turkey

    2 shared publications
  • Beyza Ener

    Department of Medical Microbiology, Uludağ University Faculty of Medicine, Bursa, Turkey

    2 shared publications
  • Burak Deveci

    Department of Hematology, Medstar Antalya Hospital, Antalya, Turkey

    2 shared publications
  • Emin Halis Akalin

    Department of Infectious Diseases and Clinical Microbiology, Uludag University Faculty of Medicine, Bursa, Turkey

    2 shared publications
  • Huseyin Nadir Kahveci

    Department of Infectious Diseases and Clinical Microbiology, Erciyes University Faculty of Medicine, Kayseri, Turkey

    2 shared publications
  • Mehmet Mucahit Guncu

    Department of Medical Microbiology, Marmara University Institute of Health Sciences, Istanbul, Turkey

    2 shared publications

Latest Publications

  • Open Access

    Endoscopic Management of Necrotizing Pancreatitis Within a Multidisciplinary Framework: A Single-Center Retrospective Study

    by Samet Yigman, Serhat Ozer, Ozlem Alhan, Ahmet Onur Demirel, Afak Karakaya, Gurkan Tellioglu, Emrah Alper

    Objective: Endoscopic step-up strategies for necrotizing pancreatitis are poorly documented in multidisciplinary real-world clinical practice. This study evaluated the feasibility and clinical outcomes of an endoscopic management strategy within a structured multidisciplinary framework for patients with necrotizing pancreatitis. Methods: This retrospective, single-center study evaluated 13 consecutive patients with necrotizing pancreatitis who underwent endoscopic treatment between January 2022 and December 2025. Demographic characteristics, disease severity via the Modified Computed Tomography Severity Index (MCTSI), details of endoscopic interventions, microbiological findings, and clinical outcomes were analyzed. Results: The median disease severity score was 8 (range, 4–10). Patients underwent a median of 6 (range, 2–15) endoscopic interventions, with the initial intervention performed at a median of 18 days (range, 1–90) from diagnosis. The median follow-up duration was 7 months (range, 1–41). Lumen-apposing metal stents followed by coaxial plastic pigtail stents were utilized in most patients. Microbiological cultures predominantly revealed Candida spp. and Klebsiella pneumoniae, including multidrug-resistant organisms in a subset. The median hospital stay was 21 days (range, 8–97), and the median intensive care unit (ICU) stay was 0 days (range, 0–44). No in-hospital mortality was observed; long-term complications occurred in a minority of patients. Conclusions: Endoscopic management within a structured multidisciplinary framework is a feasible and safe treatment strategy for necrotizing pancreatitis. Given the limited sample size, larger prospective studies are warranted to validate these findings.

  • Open Access

    Challenges in case management of brucellosis: a retrospective study from an endemic region

    by Özlem Alhan, Bekir Çoker

    Human brucellosis remains a significant public health concern in northeastern Türkiye and is among the leading causes of visits to infectious disease

  • Open Access

    Bronkoalveolar Lavaj Örneklerinde Pneumocystis jirovecii Pozitifliği ve Ampirik Tedavi Yaklaşımı

    by Buket Erturk Sengel, Özlem Alhan, Rabia Can Sarinoğlu, Elif Tükenmez Tigen, Zekaver Odabaşı

    Pneumocystis jirovecii (PJ) immünosupresif hastalarda pnömoniye sebep olan fırsatçı bir maya benzeri fungustur. En riskli grup HIV-pozitif hastalardır ancak son yıllarda HIV-negatif immünosuprese hastalarda daha sık görülmektedir. Bu çalışmada Marmara Üniversitesi Pendik Eğitim ve Araştırma Hastanesinde Pneumocystis jirovecii pnömonisi (PJP) ve diğer fırsatçı solunum yolu patojenleri şüphesi ile bronkoskopik örnekleri değerlendirilen hastalarda PJ polimeraz zincir reaksiyonu (PZR) pozitiflik oranı, hasta risk faktörleri, klinik ve laboratuvar bulgularını retrospektif olarak değerlendirilmiştir. Toplam 133 hastanın bronkoalveolar lavaj örneğinden PJ-PZR çalışılmış ve % 13 (17/133) oranında pozitiflik bulunmuştur. PZR pozitif hastaların % 41’inin HIV-pozitif ve % 59’unun HIV-negatif immünosuprese hastalar olduğu görülmüştür. Örnek gönderilen hastaların 72’sine ampirik trimetroprim/sülfametoksazol başlanmış, PZR pozitif hastalarla beraber toplam 38 hastada tedaviye devam edilmiştir. PJ-PZR negatif 21 hastanın dokuzunda klinik yanıt alınmıştır ve başka bir enfeksiyon etkeni gösterilememiştir. Toplam 66 hastaya hipoksik olmaları nedeniyle steroid verilmiştir. Ampirik tedavi baş- lanan hastaların % 24’ünde PJ-PZR pozitifliği ve % 36’sının tedaviye yanıt verdiği görülmüştür. HIV-negatif immün suprese hastalarda PJP akla gelmeli ve gerekli örnek alındıktan ve ampirik tedaviye başlandıktan sonra başka bir etken gösterilemiyorsa ve yüksek klinik şüphe varsa tedaviye devam edilebilir.

  • Antibiotic resistance in Türkiye: what has been done and what needs to be done urgently?

    by Özlem Alhan, Hasan Selçuk Özger, Onur Karatuna, Özlem Kurt Azap, Bahar Madran, Şiran Keske, Güle Çınar, İrEm Akdemir, Önder Ergönül


  • Open Access

    Emerging West Nile virus infections in Türkiye

    by Özlem Alhan, Meliha Meriç Koç, Ayşe Batırel, Emel Yılmaz, Gülden Ersöz, Mehtap Aydın, Merve Üstüner Doğan, Hande Hazır Konya, Üner Kayabaş, Ferit Kuşçu, et al.

    Purpose: Türkiye experienced its largest West Nile virus (WNV) infection outbreak in 2024. We described the clinical and laboratory features of human cases with WNV infection collected from eleven tertiary hospitals in Türkiye in 2024. Methods: The clinical characteristics of the patients were gathered using a structured form in the retrospective study. According to the ECDC case definition of WNV infections, the patients were classified as ‘confirmed’ or ‘probable’ cases. The odds ratio (OR) and 95% confidence interval (CI) for possible mortality predictors in WNV infections were calculated using multivariate logistic regression analysis. p < 0.05 was considered statistically significant. Results: The mean age of the 51 patients was 63.3 ± 13.6 years, and 37 (72.5%) were male. Twenty-six cases (51%) were confirmed, and 49% were probable WNV infection. Forty-eight patients (94.1%) had WNV neuroinvasive disease: 24 (47%) were diagnosed with meningoencephalitis, 20 (39.2%) with encephalitis, one (2%) with meningitis, and seven (13.7%) with acute flaccid paralysis. Twenty patients (39.2%) had movement disorders (tremor, myoclonus, bradykinesia, or rigidity). The case fatality rate was 17.6%. In multivariate analysis, older age (OR: 1.09, CI: 1.03–1.19, p = 0.042) and secondary bacterial infection during hospitalization (OR: 10, CI: 1.55–64.95, p = 0.015) were associated with fatality. Conclusion: We highlighted the increasing number of cases and diagnostic challenges by describing the highest number of the patients with WNV infections in Türkiye. Raising awareness among healthcare professionals, facilitating access to diagnostic tests, and developing rapid, reliable, and easily applicable tests would enable early diagnosis and help improve outcomes.


  • Diagnostic Efficacy of Aspergillus Galactomannan Lateral Flow Assay in Patients with Hematological Malignancies: A Prospective Multicenter Study

    by Ozlem Alhan, Rabin Saba, Emin Halis Akalin, Beyza Ener, Zeynep Ture Yuce, Burak Deveci, Mehmet Mucahit Guncu, Huseyin Nadir Kahveci, Asu Fergun Yilmaz, Zekaver Odabasi

    Background A rapid and reliable diagnostic test is needed to reduce mortality through early diagnosis of invasive aspergillosis (IA) in patients with hematological malignancies. Objective To evaluate the efficacy of serum and bronchoalveolar lavage (BAL) Aspergillus galactomannan lateral flow assay (GM-LFA) in IA diagnosis and determine the correlation of GM-LFA with GM enzyme immunoassay (GM-EIA) in patients with hematological malignancies. Methods In this prospective multicenter study, we used serum and BAL fluid samples from patients with hematological malignancies and suspected IA and performed GM-LFA and GM-EIA. According to the EORTC/MSGERC criteria, patients were grouped as proven (n = 6), probable (n = 22), possible IA (n = 55), or no IA (n = 88). The performance of serum GM-LFA at 0.5 optical density index (ODI) and area under the curve (AUC) were calculated. Spearman’s correlation analysis and kappa statistics were performed to determine the agreement between the tests. Results GM-LFA showed an AUC of 0.832 in proven/probable IA (sensitivity [SEN], specificity [SPE], negative predictive value [NPV], and diagnostic accuracy were 75%, 100%, 92.6%, and 93.9%, respectively, at a 0.5 ODI) versus that in no IA. A moderate positive correlation was noted between the GM-LFA and GM-EIA scores (p = 0.01). The observed agreement between the tests at 0.5 ODI was almost perfect (p < 0.001). After excluding patients who received mold-active antifungal prophylaxis or treatment, the SEN, SPE, NPV, and diagnostic accuracy for proven/probable IA were 76.2%, 100%, 93.3%, and 94.5%, respectively. Conclusions Serum GM-LFA demonstrated high discriminatory power and good diagnostic performance for IA in patients with hematological malignancies.


  • Open Access

    Diagnostic efficacy of Aspergillus galactomannan lateral flow assay in patients with hematological malignancies: a prospective multicenter study

    by Ozlem Alhan, Rabin Saba, Emin Halis Akalin, Beyza Ener, Zeynep Ture Yuce, Burak Deveci, Mehmet Mucahit Guncu, Huseyin Nadir Kahveci, Asu Fergun Yilmaz, Zekaver Odabasi

    Background: A rapid and reliable diagnostic test is needed to reduce mortality through early diagnosis of invasive aspergillosis (IA) in patients with hematological malignancies. Objective: To evaluate the efficacy of serum and bronchoalveolar lavage (BAL) Aspergillus galactomannan lateral flow assay (GM-LFA) in IA diagnosis and determine the correlation of GM-LFA with GM enzyme immunoassay (GM-EIA) in patients with hematological malignancies. Methods: In this prospective multicenter study, we used serum and BAL fluid samples from patients with hematological malignancies and suspected IA and performed GM-LFA and GM-EIA. According to the EORTC/MSGERC criteria, patients were grouped as proven (n=6), probable (n=22), possible IA (n=55), or no IA (n=88). The performance of serum GM-LFA at 0.5 optical density index (ODI) and area under the curve (AUC) were calculated. Spearman’s correlation analysis and kappa statistics were performed to determine the agreement between the tests. Results: GM-LFA showed an AUC of 0.832 in proven/probable IA (sensitivity [SEN], specificity [SPE], negative predictive value [NPV], and diagnostic accuracy were 75%, 100%, 92.6%, and 93.9%, respectively, at a 0.5 ODI) versus that in no IA. A moderate positive correlation was noted between the GM-LFA and GM-EIA scores (p=0.01). The observed agreement between the tests at 0.5 ODI was almost perfect (pConclusions: Serum GM-LFA demonstrated high discriminatory power and good diagnostic performance for IA in patients with hematological malignancies.